Revealing tumor immunity after hematopoietic stem cell transplantation.

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 15 ·No. 14 ·2009-07-15 ·Pages 4515-7

Wu CJ, Ritz J

Abstract

Allogeneic hematopoietic stem cell transplantation is currently the most effective method for inducing tumor immunity. However, the diversity of target antigens recognized by donor T cells has not been established. New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens.

MeSH Terms

Animals Cytotoxicity, Immunologic/immunology Graft vs Host Disease/immunology Hematopoietic Stem Cell Transplantation/methods Humans Leukemia, Lymphocytic, Chronic, B-Cell/blood,immunology,surgery Leukocytes, Mononuclear/cytology,immunology Models, Immunological T-Lymphocytes/cytology,immunology Transplantation, Homologous Treatment Outcome

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Wu Catherine J

Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

Ritz Jerome

Article Info

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Abbr.

Clin Cancer Res

ISSN

1557-3265

DOI

10.1158/1078-0432.CCR-09-0873

Published

2009-07-15

Epub

2009-00-07

Pages

4515-7

Language

English

Region

United States

NLM ID

9502500

Subset

Corrections

CommentOn

PMID: 19567591

External Links

PubMed source DOI: 10.1158/1078-0432.CCR-09-0873 View journal details

Analysis Services

Revealing tumor immunity after hematopoietic stem cell transplantation.

Contact

WeChat Official Account